About
About VarmX
Our team
Portfolio
News & Events
Contact
News & events
News & events
Filter by:
All
Conferences & Events
News
Scientific publications
All
10.09.2024
Management TeamNews
VarmX announces appointment of Martijn Negen as COO
Read more
25.05.2023
News
VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it...
Read more
08.07.2022
News
VarmX to Present New Data at the 2022 ISTH Congress
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it...
Read more
15.12.2021
News
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Bypassing Agent, VMX-C001
VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment...
Read more
21.10.2021
News
VarmX awarded funding from the EIC Accelerator
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded...
Read more
19.07.2021
News
VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that...
Read more
15.06.2021
News
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
Read more
27.01.2021
News
VarmX appoints Dr. Gerard Short as Chief Medical Officer
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
Read more
12.07.2020
Scientific publications
VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile
Read more
08.07.2020
News
VarmX raises € 32 million series B financing
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
Read more
02.07.2018
News
VarmX raises € 12.5 million to develop VMX-COO1
VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today...
Read more
Page
1
Page
2
Page
3
VMX-C001:
Transforming the treatment of bleeding in patients taking Factor Xa DOACs
Portfolio